Join the club for FREE to access the whole archive and other member benefits.

Michael Hufford

Professor, CMO of e-Nicotine Technology and CEO of LyGenesis.

Dr. Hufford is the Chief Medical Officer and a co-founder of e-Nicotine Technology. He has 16 years of experience in nicotine research, drug development, and entrepreneurship. Dr. Hufford’s drug development experience includes serving as Vice President of Corporate and Clinical Development at Cypress Bioscience, where his responsibilities included drug and medical device development in support of multiple CNS assets, including the clinical development and FDA approval of Savella® (milnacipran) for fibromyalgia.

Dr. Hufford earned his Bachelor’s Degree with Distinction in Psychology from Purdue University, and his Master’s and Doctoral degrees in Clinical Psychology from the University of Pittsburgh, where his research focused on smoking and other addictive behaviors. He completed his clinical internship at the McLean Hospital, where he was a Clinical and Research Fellow in the Department of Psychiatry at Harvard Medical School.

Visit website: http://enicotinetechnology.com/team/michael-hufford-phd/

 michael-hufford-4339596

 MichaelHufford

See also: Company LyGenesis - Organ regeneration using a patient's lymph nodes as bioreactors to grow ectopic organs

Details last updated 23-Oct-2019

Michael Hufford is also referenced in the following:

Longevity Leaders World Congress 2022

26-Feb-2022 to 27-Feb-2022

Event for leaders in longevity science, technology, business and finance organized by Longevity Leaders (LSX)

Michael Hufford News

Morphoceuticals raises $8M to advance bioelectrical treatment for regenerating tissues or organs

Morphoceuticals raises $8M to advance bioelectrical treatment for regenerating tissues or organs

Longevity Technology - 15-Feb-2023

A revolutionary approach in regenerative medicine that could improve quality of life in patients

FDA approved LyGenesis' phase 2a trials on liver failure patients

FDA approved LyGenesis' phase 2a trials on liver failure patients

Longevity Technology - 30-Dec-2020

Raised $11M funding which goes into trials and developing functional organs

Lygenesis announces four peer reviewed papers on organ regeneration

Lygenesis announces four peer reviewed papers on organ regeneration

Longevity Technology - 28-Aug-2020

Takes us a step ahead towards regenerating organs for human diseases

Possible future of transplantation medicine

Possible future of transplantation medicine

Fight Aging! - 04-Oct-2019

LyGenesis is developing a technique for implanting cells into lymph nodes for future transplantation